103 related articles for article (PubMed ID: 15501060)
1. Farnesyl protein transferase inhibitors targeting the catalytic zinc for enhanced binding.
Njoroge FG; Vibulbhan B; Pinto P; Strickland C; Kirschmeier P; Bishop WR; Girijavallabhan V
Bioorg Med Chem Lett; 2004 Dec; 14(23):5877-80. PubMed ID: 15501060
[TBL] [Abstract][Full Text] [Related]
2. Bridgehead modification of trihalocycloheptabenzopyridine leads to a potent farnesyl protein transferase inhibitor with improved oral metabolic stability.
Njoroge FG; Vibulbhan B; Shi X; Strickland C; Kirschmeier P; Bishop R; Nomeir A; Girijavallabhan V
Bioorg Med Chem Lett; 2004 Dec; 14(23):5899-902. PubMed ID: 15501065
[TBL] [Abstract][Full Text] [Related]
3. Enhanced FTase activity achieved via piperazine interaction with catalytic zinc.
Njoroge FG; Vibulbhan B; Pinto P; Strickland C; Bishop WR; Nomeir A; Girijavallabhan V
Bioorg Med Chem Lett; 2006 Feb; 16(4):984-8. PubMed ID: 16298128
[TBL] [Abstract][Full Text] [Related]
4. Non-thiol farnesyltransferase inhibitors: utilization of the near aryl binding site by 5-arylacetylaminobenzophenones.
Mitsch A; Böhm M; Sattler I; Schlitzer M
Arch Pharm (Weinheim); 2004 Apr; 337(4):213-8. PubMed ID: 15065081
[TBL] [Abstract][Full Text] [Related]
5. [Three dimensional quantitative structure-activity relationship of farnesyl protein transferase inhibitors].
Wan SB; Yi X; Guo ZR
Yao Xue Xue Bao; 2001 Jun; 36(6):423-6. PubMed ID: 12585125
[TBL] [Abstract][Full Text] [Related]
6. Potent and selective farnesyl transferase inhibitors.
Millet R; Domarkas J; Houssin R; Gilleron P; Goossens JF; Chavatte P; Logé C; Pommery N; Pommery J; Hénichart JP
J Med Chem; 2004 Dec; 47(27):6812-20. PubMed ID: 15615530
[TBL] [Abstract][Full Text] [Related]
7. Successful molecular dynamics simulation of the zinc-bound farnesyltransferase using the cationic dummy atom approach.
Pang YP; Xu K; Yazal JE; Prendergas FG
Protein Sci; 2000 Oct; 9(10):1857-65. PubMed ID: 11106157
[TBL] [Abstract][Full Text] [Related]
8. Synthetic active site-directed inhibitors of metzincins: achievement and perspectives.
Yiotakis A; Dive V
Mol Aspects Med; 2008 Oct; 29(5):329-38. PubMed ID: 18657570
[TBL] [Abstract][Full Text] [Related]
9. Farnesyl transferase inhibitors: current developments and future perspectives.
Eskens FA; Stoter G; Verweij J
Cancer Treat Rev; 2000 Oct; 26(5):319-32. PubMed ID: 11006134
[TBL] [Abstract][Full Text] [Related]
10. Module assembly for protein-surface recognition: geranylgeranyltransferase I bivalent inhibitors for simultaneous targeting of interior and exterior protein surfaces.
Machida S; Usuba K; Blaskovich MA; Yano A; Harada K; Sebti SM; Kato N; Ohkanda J
Chemistry; 2008; 14(5):1392-401. PubMed ID: 18200641
[TBL] [Abstract][Full Text] [Related]
11. Farnesyl protein transferase inhibitory components of Polygonum multiflorum.
Kwon BM; Kim SH; Baek NI; Lee SI; Kim EJ; Yang JH; Chae BS; Lee JH; Park HW; Park JS; Kim DK
Arch Pharm Res; 2009 Apr; 32(4):495-9. PubMed ID: 19407965
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of piperidine farnesyltransferase inhibitors with reduced glucuronidation potential.
Tanaka R; Rubio A; Harn NK; Gernert D; Grese TA; Eishima J; Hara M; Yoda N; Ohashi R; Kuwabara T; Soga S; Akinaga S; Nara S; Kanda Y
Bioorg Med Chem; 2007 Feb; 15(3):1363-82. PubMed ID: 17127066
[TBL] [Abstract][Full Text] [Related]
13. Current progress on farnesyl protein transferase inhibitors.
Singh SB; Lingham RB
Curr Opin Drug Discov Devel; 2002 Mar; 5(2):225-44. PubMed ID: 11926129
[TBL] [Abstract][Full Text] [Related]
14. Interaction of phosphonate analogues of the tetrahedral reaction intermediate with 5-enolpyruvylshikimate-3-phosphate synthase in atomic detail.
Priestman MA; Healy ML; Becker A; Alberg DG; Bartlett PA; Lushington GH; Schönbrunn E
Biochemistry; 2005 Mar; 44(9):3241-8. PubMed ID: 15736934
[TBL] [Abstract][Full Text] [Related]
15. Development of selective RabGGTase inhibitors and crystal structure of a RabGGTase-inhibitor complex.
Guo Z; Wu YW; Tan KT; Bon RS; Guiu-Rozas E; Delon C; Nguyen TU; Wetzel S; Arndt S; Goody RS; Blankenfeldt W; Alexandrov K; Waldmann H
Angew Chem Int Ed Engl; 2008; 47(20):3747-50. PubMed ID: 18399557
[No Abstract] [Full Text] [Related]
16. Non-thiol 3-aminomethylbenzamide inhibitors of farnesyl-protein transferase.
Ciccarone TM; MacTough SC; Williams TM; Dinsmore CJ; O'Neill TJ; Shah D; Culberson JC; Koblan KS; Kohl NE; Gibbs JB; Oliff AI; Graham SL; Hartman GD
Bioorg Med Chem Lett; 1999 Jul; 9(14):1991-6. PubMed ID: 10450968
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the complex of a trifluoromethyl-substituted shikimate-based bisubstrate inhibitor and 5-enolpyruvylshikimate-3-phosphate synthase by REDOR NMR.
McDowell LM; Studelska DR; Poliks B; O'Connor RD; Schaefer J
Biochemistry; 2004 Jun; 43(21):6606-11. PubMed ID: 15157093
[TBL] [Abstract][Full Text] [Related]
18. Selective modification of CaaX peptides with ortho-substituted anilinogeranyl lipids by protein farnesyl transferase: competitive substrates and potent inhibitors from a library of farnesyl diphosphate analogues.
Troutman JM; Subramanian T; Andres DA; Spielmann HP
Biochemistry; 2007 Oct; 46(40):11310-21. PubMed ID: 17854205
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of potential bisubstrate inhibitors of protein farnesyltransferase. Design and synthesis of functionalized imidazoles.
de Figueiredo RM; Coudray L; Dubois J
Org Biomol Chem; 2007 Oct; 5(20):3299-309. PubMed ID: 17912382
[TBL] [Abstract][Full Text] [Related]
20. Protein farnesyl transferase inhibitors for the treatment of malaria and African trypanosomiasis.
Buckner FS; Eastman RT; Yokoyama K; Gelb MH; Van Voorhis WC
Curr Opin Investig Drugs; 2005 Aug; 6(8):791-7. PubMed ID: 16121685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
